The 26th Annual Meeting of the Japanese Society for Pharmacoepidemiology 'Regulatory Science Meets Epidemiology.' 28th to 29th, Nov.2020 Congress President of JSPE 2020President of JSPE 2020 Hisashi Urushihara Dt.PH, Professor(Division of Drug Development and Regulatory Science)

The 26th annual meeting of JSPE postponed due to COVID-19 concerns.

With so many factors related to the COVID-19 pandemic still unknown, and considering the health and safety of our attendees, the Japanese Society for Pharmacoepidemiology (JSPE) has made the difficult decision to postpone the 26th annual meeting in Tokyo until 2021.

Instead of the annual meeting 2020, we will host a virtual mini-symposium on 28th November 2020.

Please continue to check this page for updates.

Sincerely,

Hisashi Urushihara, Dr.PH
President and the Chairperson
The 26th Annual Meeting of Japanese Society for Pharmacoepidemiology

Greeting from President and the Chairperson

Welcome to the 26th annual meeting of Japanese Society for Pharmacoepidemiology!

We are pleased to announce that the 26th annual meeting of Japanese Society for Pharmacoepidemiology will be held at Shiba-Kyoritsu Campus, Keio University on 28th and 29th November 2020.

Hisashi Urushihara, DrPH, Professor, Keio University School of Pharmacy, Division of Drug Development and Regulatory Science, President and the chairperson of the annual meeting, is delighted to host the meeting and looking forward to welcome you as our guests at the meeting.

Pharmacoepidemiology is the discipline aiming to ensure rational use of medicines and medical devices and consequently to bring healthier life and better QoL to patients, which is based on epidemiological methodologies as science base and international/local pharmaceutical laws/regulations as the foundation for practical applications. As the statutory/regulatory system governing healthcare, and technologies/methodologies used for evaluating drug safety/efficacy have been evolving at a breakneck speed recently, we are witnessing that the span of research area and data sources used in pharmacoepidemiology is greatly affected and enlarged. We are undergoing a paradigm shift.

The 2017 ICH Reflection paper on Good Clinical Practice (GCP) renovation positioned observational researches using a high volume of routinely collected data in clinical practice setting under the umbrella of the prospective revision of the ICH E6 guidelines for GCP and thus the coming GCP guidelines are expected to incorporate the standards for observational studies for the purpose of regulatory decision making not only for post-marketing safety but also for marketing authorization.The data sources, study design, and analytical methods, which have long been familiar with pharmacoepidemiologists and frequently used in pharmacoepidemiological studies, now come at the center of attention in the area of regulatory science.

Please join us to further excavate a new, hidden treasure in familiar ground.

Kindly regards,
January 20, 2020

Hisashi Urushihara, Dr.PH
President and the Chairperson
The 26th Annual Meeting of Japanese Society for Pharmacoepidemiology
Professor
Division of Drug Development and Regulatory Science
School of Pharmacy Keio University.

Hisashi Urushihara, Dr.PH
IQVIA JMP